EUVIMEDEUVIMED entdecken
Crossref

Radiotherapy-ignited dual-stage prodrug nanoplatform for cascade activation of toll-like receptor 7/8 agonist and reignition of antitumor immunity

Zhongshi Qiao, Danping Liu, Rui Huang, Yingxin Chen, Hui Li, Meiyun Hao, Xinke Zhang, Xiaoqing Li, Zhiyue Zhang, Xuezhen Ma

Journal of Controlled Release · 2026-11 · 399 · 115409

DOI: 10.1016/j.jconrel.2026.115409 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Controlled Release, 2026-11. Verfasst von Zhongshi Qiao und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, Qingdao Central Hospital, University of Health and Rehabilitation Sciences, Affiliated Qingdao Central Hospital of Qingdao Un…. Hauptthemen laut MEDLINE: Prodrugs, Toll-Like Receptor 7, Imiquimod, Toll-Like Receptor 8. Die Arbeit nennt 49 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Shandong Province Natural Science Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

A major bottleneck in radio-immunotherapy is the inability to precisely couple the localized stimulus of radiotherapy (RT) with the systemic action of immunotherapeutics. To bridge this gap, we developed a chemically engineered RT-ignited nanoplatform that productively harnesses the biochemical consequences of RT to precisely activate immunotherapy locally, thereby amplifying its benefits while minimizing systemic exposure. The platform co-delivers a hydrogen sulfide (H₂S)-responsive prodrug of toll-like Toll-like receptor 7/8 (TLR7/8) agonist imiquimod (IMQ) using a reactive oxygen species (ROS)-sensitive, targeted nanocarrier. RT ignites a biochemical sequence: ROS bursts disassemble the carrier, and the subsequent H₂S upregulation cleaves the prodrug, ensuring tumor-localized drug release. This RT-primed, sequentially activated therapy profoundly enhances antitumor immunity by inducing immunogenic cell death (ICD), activating antigen-presenting cells (APCs), and overcoming systemic immunosuppression, culminating in durable tumor regression and immunological memory. This study highlights a chemistry-driven approach to spatially and temporally confine immune activation to the tumor site, effectively broadening the therapeutic window and transforming RT-induced biochemical changes into a precise trigger for systemic immunity.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ProdrugsToll-Like Receptor 7ImiquimodToll-Like Receptor 8NeoplasmsAntineoplastic AgentsAnimalsToll-Like Receptor AgonistsCell Line, TumorMice, Inbred C57BLFemaleImmunotherapyMiceHumansReactive Oxygen Species

Stichwörter der Autor:innen

Cancer immunotherapyH₂SNanomedicineRadiotherapyTLR7/8 agonist

Substanzen

ProdrugsToll-Like Receptor 7Toll-Like Receptor AgonistsImiquimodToll-Like Receptor 8Reactive Oxygen SpeciesAntineoplastic Agents

Autor:innen und Institutionen

  • Department of Oncology, Qingdao Central Hospital, University of Health and Rehabilitation Sciences, Affiliated Qingdao Central Hospital of Qingdao University, Qingdao, Shandong 266042, China.
  • State Key Laboratory of Discovery and Utilization of Functional Components in Traditional Chinese Medicine, Key Laboratory of Chemical Biology (Minis-try of Education), Shandong Key Laboratory of Targeted Drug Delivery…
  • Key Laboratory of Chemical Biology (Ministry of Education), NMPA Key Laboratory for Quality Research and Evaluation of Carbohydrate-based Medicine, Department of Pharmacology, School of Pharmaceutical Sciences, Shandong…
  • State Key Laboratory for Innovation and Transformation of Luobing Theory; Key Laboratory of Cardiovascular Remodeling and Function Research, Chinese Ministry of Education, Chinese National Health Commission and Chinese…
  • Department of Oncology, Qingdao Central Hospital, University of Health and Rehabilitation Sciences, Affiliated Qingdao Central Hospital of Qingdao University, Qingdao, Shandong 266042, China. Electronic address: maxuezh…

Förderung

  • National Natural Science Foundation of China
  • Shandong Province Natural Science Foundation

Zitieren

APA

Qiao, Z., Liu, D., Huang, R., Chen, Y., Li, H., Hao, M., Zhang, X., Li, X., Zhang, Z., & Ma, X. (2026). Radiotherapy-ignited dual-stage prodrug nanoplatform for cascade activation of toll-like receptor 7/8 agonist and reignition of antitumor immunity. Journal of Controlled Release, 399, 115409. https://doi.org/10.1016/j.jconrel.2026.115409

Vancouver

Qiao Z, Liu D, Huang R, Chen Y, Li H, Hao M, et al. Radiotherapy-ignited dual-stage prodrug nanoplatform for cascade activation of toll-like receptor 7/8 agonist and reignition of antitumor immunity. Journal of Controlled Release. 2026;399:115409. doi:10.1016/j.jconrel.2026.115409

BibTeX
@article{Qiao2026,
  author = {Qiao, Zhongshi and Liu, Danping and Huang, Rui and Chen, Yingxin and Li, Hui and Hao, Meiyun and Zhang, Xinke and Li, Xiaoqing and Zhang, Zhiyue and Ma, Xuezhen},
  title = {Radiotherapy-ignited dual-stage prodrug nanoplatform for cascade activation of toll-like receptor 7/8 agonist and reignition of antitumor immunity},
  journal = {Journal of Controlled Release},
  year = {2026},
  volume = {399},
  pages = {115409},
  doi = {10.1016/j.jconrel.2026.115409}
}
Kostenlos starten →